A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors
Latest Information Update: 01 Feb 2024
At a glance
- Drugs Binimetinib (Primary) ; JAB 3312 (Primary) ; Osimertinib (Primary) ; Pembrolizumab (Primary) ; Sotorasib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
- 01 Feb 2024 This study has been discontinued in France(Date of the global end of the trial: 2023-12-19), according to European Clinical Trials Database record.
- 30 Aug 2023 According to Jacobio media release, the preliminary clinical results will be presented in the form of a Proffered Paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress in October 2023.
- 16 May 2023 Planned End Date changed from 30 Jun 2023 to 5 Feb 2024.